Benoit Côte initiates the commercial strategy of the company and
introduces a new line of products to the human health market
QUEBEC CITY, Feb. 21 /CNW Telbec/ - M. Benoit Côte announces the creation
of BIOTANIKA INC., a company specialized in the development and the
commercialization of natural base products. This company is composed of two
commercial units: one dedicated to the human health market, and one to the
animal health sector.
"Created in October 2006, PEGASE MEDICAL was the first piece of a
well-prepared game plan Our strategy was to set a commercial base in this
fast-growing market and to identify the best approach to tackle the huge
nutraceutical market in the human health sector" explains Mr. Benoit Côte,
President and Chief Executive Officer of BIOTANIKA INC. "BIOTANIKA becomes
then a company dedicated to the commercialization of nutraceutical products
with high scientific value, having the potential to compete with prescription
products, relying on an organic and acquisition growth plan.
BIOTANIKA AND THE HUMAN MARKET
"We evaluated various possibilities of partnerships and obtained the
commercial rights on formulations, trade secrets and manufacturing processes
for 60 natural base products in total", adds Mr Côte. "Our knowledge of the
synergic modes of action and combined effects of various plant extracts
enables us to create really efficient products targeting specific health
problems", explains Mr. Guy Chamberland, Vice President - Regulatory Affairs
and Product Development. "Unlike the current strategy of companies
commercializing products with one herb only, BIOTANIKA combines botanical
ingredients. For several months, Asian and American contract research
organisations have tested and compared our products with prescription drugs
and the results are very encouraging" concludes Mr. Chamberland.
OUR FIRST TARGET: PAIN MANAGEMENT
BIOTANIKA will proceed with a controlled market launch for its pain
management products, before making them available in pharmacies in the Spring
2008. COOLSENS, a product for muscular and rheumatoid pains, ARTRIPHEN, for
chronic pain of arthritis, and DOLOROX, an anti-inflammatory for acute pain
will be brought to market in Canada first and then in the United States.
A MARKET WITH A HUGE POTENTIAL
"The sector of pain management and anti-inflammatory products for
moderate to severe cases represents a market of almost $ 6 billions in the
United States only with an 8% yearly growth. Since the VIOXX recall and the
questionable efficiency of other products available in pharmacies or on
prescription, only few alternatives for pain management are available.
Additionally, because of various side effects, including gastric problems
associated to these products, the launch of efficient side effect free
products will be very attractive and considerably improve the well-being of
people suffering from chronic pain and other related health problems. We aim
at improving their quality of life", explains Mr. Yves Prud'homme,
Vice-President Sales and Marketing of BIOTANIKA, a pharmacist and former
national sales manager of an important pharmaceutical company in Canada.
COMPANION ANIMAL MARKET: A MARKET WITH A REGULAR GROWTH
One year only after starting its operations, the company owns a portfolio
of more than 30 products dedicated to the horse, dog and cat markets through
various exclusivity agreements signed with European companies. These products
are now authorized for sale in Canada and in the United States. Various
collaboration and distribution agreements for the North American territory
will be signed in 2008.
According to an article published by Business Week (August 2007), annual
expenses related to companion animals will overcome US$ 41 billion in North
America and will growth at a regular rate of 13 % per year for the two coming
years at least. Expenses related to natural health products only represent a
US$ 1 billion market per year, and it continues growing.
ABOUT BIOTANIKA INC.
BIOTANIKA is a private company developing and commercializing natural
base products dedicated to the companion animal and human health markets. The
company owns two independent commercial units: BIOTANIKA - Animal health et
BIOTANIKA - Human Health.
The business model of the company is based on rigorous development and
scientifically proven efficiency of products, an ethic regulatory process, a
controlled and profitable organic growth, and an approach of creation of value
For further information: Benoit Côte, President and CEO, BIOTANIKA INC.,
(418) 653-3423, Fax: (418) 653-9238, firstname.lastname@example.org